Kristen Marks, MD
Infectious Disease · New York, NYNPI 1255421426
Payments from drug & device makers
What this record shows
This record is dominated by grants: $301 of the $456 with a category attached, or 66.0%. Janssen Scientific Affairs, LLC accounts for 66.0% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $152.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$301
- Viiv Healthcare Company$155
Across 37 payments — averaging $76,398 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2.8M
- Viiv Healthcare Company$44K
What the payments were for
- Grants$30166%
- Food & beverage$15534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $301 |
| Viiv Healthcare Company | 2 | $155 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABENUVA$125
How this compares
$456 in reported general payments places this provider in the 60th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 69 | $308,150 |
| TivicayDolutegravir Sodium | 27 | $59,925 |
| DescovyEmtricitabine/Tenofov Alafenam | 27 | $58,028 |
| IsentressRaltegravir Potassium | 13 | $25,382 |
| PrezistaDarunavir | 12 | $22,988 |
| EdurantRilpivirine Hcl | 12 | $16,070 |
| Darunavir | 21 | $14,289 |
| Ritonavir | 32 | $5,076 |
| ValacyclovirValacyclovir Hcl | 18 | $1,034 |
| Enalapril Maleate | 13 | $37 |
| Quetiapine Fumarate | 11 | $26 |
| Amlodipine Besylate | 12 | $22 |
| Simvastatin | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay | $155 | $59,92527 claims |
| Janssen Scientific Affairs, LLCPrezista, Edurant | $301 | $39,05824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.